Post hoc trial findings support aprocitentan’s potential cardiovascular and kidney-protective effects in patients with chronic kidney disease (CKD) with resistant hypertension.

Formal written minutes from the U.S. FDA confirms no major concerns identified for the planned Phase 3 PANDA study of ...

SaveHealth reports on 10 hypertension medications, their classifications, effectiveness, side effects, and safety in managing ...

Please provide your email address to receive an email when new articles are posted on . Resistant and refractory hypertension represent distinct disease states requiring different treatments. A ...

Idorsia receives approval from Health Canada for JERAYGO™ (aprocitentan) as the first and only endothelin receptor antagonist ...

Findings showed baxdrostat at both doses significantly reduced mean systolic blood pressure compared with placebo at week 12. Topline data were announced from a phase 3 trial that evaluated baxdrostat ...

Findings showed treatment with lorundrostat resulted in statistically significant reductions in systolic blood pressure compared with placebo. Topline data were announced from a phase 3 trial ...

Blocking the endothelin pathway could represent a new mode of action to lower blood pressure in resistant hypertension, according to investigators. Aprocitentan, a dual endothelin receptor A and B ...

Resistant hypertension is a serious form of high blood pressure that persists despite the use of at least three antihypertensive medications from different classes, including a diuretic. In a recent ...

NKF 2017-obese patient in doctor office, obesity blood pressure Most patients with CKD and apparent treatment-resistant hypertension had uncontrolled resistant hypertension or refractory hypertension.

Idorsia receives approval from Health Canada for JERAYGO (aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment of resistant hypertension.JERAYGO is a new oral ant ...